InsiderSignalSign in

← Insider buys

ACLX

Arcellx Inc · Healthcare

Insiders sold $14.6M of Arcellx Inc in the last 12 months and bought none

$0Bought, 12 mo

$14.6MSold, 12 mo

$6.7BMarket cap

ACLX over the last year

No insider buys filed in this year

ACLX after insider buys

3 months after each buy, from the first price a copier could get.

2 buys have 3 months of prices so far. A record shows here at 3.

Every filing

68 insider filings since 2022, newest first

Rami Elghandour · Insider

$10.2M−11.0%Feb 27

Michelle Gilson · CFO

$1.3M−25.0%Feb 25

Michelle Gilson · CFO

$573K−16.0%Feb 19

Michelle Gilson · CFO

$785K−17.0%Feb 18

David Charles Lubner · Director

$450K−22.0%Jan 20

Christopher Heery · Chief Medical Officer

$403K−20.0%Jan 14

Christopher Heery · Chief Medical Officer

$487K−20.0%Jan 13

Christopher Heery · Chief Medical Officer

$393K−14.0%Jan 12

Michelle Gilson · CFO

$157K−37.0%Nov 19

Kavita Patel · Director

$159K−100.0%Nov 14

Michelle Gilson · CFO

$1.2M−88.0%Nov 12

Kavita Patel · Director

$6.0M−100.0%Nov 12

Kavita Patel · Director

$135K−100.0%Oct 22

Kavita Patel · Director

$123K−100.0%Oct 3

Michelle Gilson · CFO

$1.2M−68.0%Sep 17

Kavita Patel · Director

$112K−100.0%Sep 12

Christopher Heery · Chief Medical Officer

$240K−27.0%Sep 6

Christopher Heery · Chief Medical Officer

$1.8M−75.0%Sep 3

Christopher Heery · Chief Medical Officer

$1.5M−70.0%Aug 28

Kavita Patel · Director

$99K−100.0%Aug 22

Christopher Heery · Chief Medical Officer

$355K−37.0%Aug 19

Christopher Heery · Chief Medical Officer

$1.2M−68.0%Aug 2

Kavita Patel · Director

$93K−100.0%Aug 1

Christopher Heery · Chief Medical Officer

$712K−54.0%Jul 18

Christopher Heery · Chief Medical Officer

$327K−37.0%Jul 12

Kavita Patel · Director

$85K−100.0%Jul 11

Christopher Heery · Chief Medical Officer

$1.1M−68.0%Jul 3

Kavita Patel · Director

$543K−100.0%Jun 28

Michelle Gilson · CFO

$692K−65.0%Jun 28

Christopher Heery · Chief Medical Officer

$1.1M−68.0%Jun 14

Michelle Gilson · CFO

$615K−38.0%May 24

Christopher Heery · Chief Medical Officer

$933K−67.0%May 3

Olivia C Ware · Director

$522K−100.0%Apr 18

Rami Elghandour · Insider

$1.5M−25.0%Apr 3

Christopher Heery · Chief Medical Officer

$3.3M−84.0%Mar 26

Jill Carroll · Director

$35.6M−25.0%Mar 25

Michelle Gilson · CFO

$473K−42.0%Mar 18

Olivia C Ware · Director

$634K−100.0%Mar 18

Christopher Heery · Chief Medical Officer

$640K−25.0%Feb 12

Rami Elghandour · Insider

$2.4M−29.0%Feb 12

Christopher Heery · Chief Medical Officer

$420K−30.0%Jan 8

Michelle Gilson · CFO

$471K−34.0%Jan 8

Rami Elghandour · Insider

$1.6M−33.0%Jan 8

Christopher Heery · Chief Medical Officer

$6.0M−94.0%Dec 19

Jill Carroll · Director

$24.8M−20.0%Dec 18

Christopher Heery · Chief Medical Officer

$106K−28.0%Aug 7

Christopher Heery · Chief Medical Officer

$95K−28.0%Jul 5

Rami Elghandour · Insider

$115K−7.0%Jun 2

Jill Carroll · Director

$14.2M−12.0%Jun 2

Michelle Gilson · CFO

$626K−61.0%May 25

About Arcellx Inc

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company preclinical product includes ACLX-004 for the treatment of AML and MDS. Further, the company focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize nito-cel and next-generation autologous and non-autologous CAR-T cell therapy products. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. As of April 28, 2026, Arcellx, Inc. operates as a subsidiary of Gilead Sciences, Inc.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.